Italiano
EnglishToday we are a great international Group
Our history started many years ago
Foundation of SORIN, a nuclear energy production center in Saluggia (Vercelli, Italy), by a JV between FIAT and Montecatini
The opening of Europe’s first in vitro diagnostics center
DiaSorin, the diagnostics division of SORIN Group, is sold to the multinational American Standard International
A management buyout brings DiaSorin ownership back to Italy
On July 19, DiaSorin is listed on the Italian stock exchange (Piazza Affari, Milan)
DiaSorin continues to grow organically and inorganically, expanding geographically and investing in technology and product innovation. It forms numerous partnerships with leading players in the global diagnostics market (Roche, Beckman Coulter, Meridian Bioscience)
DiaSorin enters the molecular diagnostics sector by acquiring the American Focus Diagnostics, now DiaSorin Molecular, adding to the Group’s competence and excellence
DiaSorin included in the FTSE MIB
DiaSorin enters a partnership with Qiagen for latent tuberculosis testing
DiaSorin acquires Siemens Healthineers’ ELISA business
DiaSorin signs an exclusive license agreement with TTP for the development of a molecular Point-of-Care (POC) solution
DiaSorin launches the LIAISON IQ analyzer with Lumos Diagnostics for POC immunodiagnostics
DiaSorin acquires the US company Luminex Corporation for $1.8bn, thus gaining multiplexing technology for molecular diagnostics and that in the Licensed Technology field
DiaSorin launches the Lyme test in partnership with QIAGEN and the MeMed BV test in partnership with MeMed
DiaSorin commercializes molecular reagent for monkeypox virus.
DiaSorin furthers its collaborations with BARDA to support clinical validation and FDA 510(k) clearance of the LIAISON® NES.
DiaSorin and B·R·A·H·M·S partnerships on a new immunodiagnostic solution to improve patient care.
Sale of Flow Cytometry business to Cytek.